Rebecca Nicholson is CEO and co-founder of 5D Ventures, a social impact and investing platform that focuses mainly on the psychedelic retreat industry. The firm’s portfolio includes Beckley Retreats in Jamaica/Netherlands, Holos in Costa Rica and Dimensions in Ontario (among others). Nicholson recently talked about growing up among psychonauts, her early days helping to set […]
Stefany Nieto is the founder of Gwella / Mojo Microdose, a health and wellness company that offers mushroom-based products, content and tools. In 2020, she and her cofounders unveiled their Mojo line of gummies, which promise a microdose experience with a blend of functional mushrooms, herbs, and roots. The product is now available in more […]
Paul F. Austin is the founder and CEO of Third Wave, a psychedelics education and community platform that offers training courses, podcasts, and detailed information on psychedelic use. He is also the author of “Mastering Microdosing,” and currently serves as an advisor to Cybin Corp. Austin recently shared some of his earliest experiences with psychedelics, […]
The second annual reMind Psychedelics Business Forum, a two-day conference and networking event, will take place on November 28-29 at the Westgate Las Vegas Resort + Casino, in partnership with MJBizCon. The forum brings together the entrepreneurs, business owners, investors, policymakers and healthcare professionals at the forefront of the rapidly evolving psychedelics marketplace. Includes: Breakfast, […]
Josh Hardman is the founder and editor of Psychedelic Alpha, a newsletter, web resource and boutique consultancy, where he explores the curious intersection of psychedelics and business, sharing regular updates and working with a group of subject-matter experts to maintain numerous free resources and datasets to help individuals and organizations make sense of this burgeoning […]
The two-page legislation simply says that no federal funds can be used to “prevent any State or unit of local government from implementing such State’s or unit of local government’s own laws that authorize the use, distribution, sale, possession, research, or cultivation of psilocybin.”
The Multidisciplinary Association for Psychedelic Studies (MAPS) this week announced the successful completion of Phase 3 clinical trials for an MDMA treatment to help patients suffering from post-traumatic stress disorder, and said it brings the group a major step closer to filing a federal request to bring the treatment to market.
A powerful House committee has cleared two psychedelics amendments for floor consideration as part of a large-scale spending bill covering the Department of Defense (DOD).
Michigan lawmakers have passed a resolution urging the U.S. Congress, the Department of Defense (DoD) and the VA to prioritize research and funding on “non-technology treatment options” for veterans with psychological trauma from military service.
The bill would legalize the possession and cultivation of small amounts of certain entheogenic plants and fungi for adults 21 and older.
Leaders of the Colorado Natural Medicine Division, part of the state Department of Revenue, say the meetings are meant to engage stakeholders and keep the public informed.
Former Colorado Avalanche defenseman Kyle Quincey teamed up with Boulder biochemist Jeremy Widmann to build the 280 acres retreat center, the “Do Good Ranch,” on Colorado’s Western Slope in anticipation of the state’s legal psilocybin-assisted treatment market rollout in 2025.
Not only did Mayor Jacob Frey take unilateral action, but according to a representative from the Mayor’s office, he suffered no political backlash. Another sign of how the psychedelic landscape is changing.
Psychedelic Club of Denver says competition will collect meaningful data about different mushrooms
Two-thirds of participants with major depressive disorder or generalized anxiety disorder reported improvement.
So far, 20 out of 24 appointments to the body have been made, with key outstanding positions still vacant despite a statutory requirement saying they had to be filled by July 15.
The BBC episode moves between past and present use and research on psychedelics.
The psychoactive compounds within the mind-altering shroom, also known as fly agaric, are not prohibited (except in Louisiana).
The purpose was to ascertain the potency of the psilocybin product and refine the group’s intake process and “flow.”
The amendments shift SB 58 from legislation focused on removing naturally occurring psychedelic medicines from the state’s criminal code, to one which sets the state up to build a regulated therapeutic model similar to what is under development in Oregon and Colorado.
Mayor Jacob Frey (D) signed the order on Friday, sending a strong message that the city does not consider substances like psilocybin to be deserving of criminalization.
New research suggests that although it may be relatively safe to use serotonergic antidepressants in pre-treatment time for patients with psychiatric disorders, SSRIs and SNRIs may diminish psilocybin’s effects.
Participants who received a combination of LSD and MDMA scored higher on measures of well-being, happiness and trust during their experience, compared to those who took LSD alone.
While researchers say the guidance will not drastically change how they study the substances, it does have an impact on two major hurdles facing the burgeoning industry: public perception and funding.